Proteomics International Laboratories' (ASX:PIQ) March quarter update contained no major surprises as the company largely reiterated its guided timelines, Euroz Hartleys said in a Thursday note.
The research firm noted that the recent placement and share purchase plan should provide the company with adequate cash for 12 months, with about AU$8.6 million in pro forma cash, assuming the plan is successful.
The research firm said their investment case is based on the company securing a US licensing partner for its product PromarkerD and for its broader test pipeline, over the medium term.
Euroz Hartleys changed Proteomics International Laboratories' rating to speculative buy from hold and cut its price target to AU$0.50 from AU$0.72.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.